A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

NCT07637578 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma (MM)
Multiple Myeloma Refractory
Multiple Myeloma in Relapse
Multiple Myeloma

Interventions

DRUG: Elranatamab
DRUG: Tocilizumab

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]